Skip to main content
MeiraGTx Holdings plc logo

MeiraGTx Holdings plc — Investor Relations & Filings

Ticker · MGTX ISIN · KYG596651029 LEI · 54930007YV6NYIOGFZ57 US Manufacturing
Open in API
Filings indexed 453 across all filing types
Latest filing 2026-05-14 Interim / Quarterly Rep…
Country KY Cayman Islands
Listing US MGTX

About MeiraGTx Holdings plc

https://meiragtx.com/

MeiraGTx Holdings plc is a clinical-stage genetic medicine company developing therapies for both rare and prevalent diseases. The company's primary focus areas include disorders of the eye, salivary gland, and central nervous system. MeiraGTx utilizes a proprietary riboswitch gene regulation platform designed to provide precise spatial and temporal control of gene expression. As a vertically integrated entity, it possesses end-to-end capabilities, including its own cGMP manufacturing facilities, to support a broad pipeline of therapeutic candidates. The company has multiple programs in clinical development, with several in late-stage trials.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q1 2026
2026-05-14 English
8-K
Regulatory Filings Classification · 94% confidence The document is a U.S. Securities and Exchange Commission Form 8-K current report. It references Item 2.02 Results of Operations and Financial Condition and furnishes an earnings press release as Exhibit 99.1. It does not contain the full financial statements itself nor is it a standalone earnings release; rather it is a regulatory filing notifying the SEC and investors of material events (the issuance of a press release). Therefore, it falls under the general Regulatory Filings category (RNS).
2026-05-14 English
ARS - MeiraGTx Holdings plc (0001735438) (Filer)
Annual Report
2026-04-30 English
DEF 14A - MeiraGTx Holdings plc (0001735438) (Filer)
Proxy Solicitation & Information Statement
2026-04-30 English
8-K - MeiraGTx Holdings plc (0001735438) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement, specifically a strategic collaboration and amendments to framework agreements related to a collaboration and license agreement. It includes detailed descriptions of the agreements and share purchase arrangements but does not contain financial statements or quarterly/yearly financial results. The document is not an annual or interim report, earnings release, or management discussion. It is a regulatory filing announcing a material contract event. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is over 10,000 characters, so it is not a brief announcement or report publication announcement.
2026-04-24 English
424B5 - MeiraGTx Holdings plc (0001735438) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to an offering of ordinary shares. It includes detailed information about the share offering, underwriting, risk factors, use of proceeds, and legal matters. It references SEC filings and incorporates by reference the company's Annual Report on Form 10-K and other filings. The document is a registration statement supplement for a securities offering, which is a capital raising activity. This type of document is classified as a Capital/Financing Update (CAP) because it provides updates on the company's fundraising and capital structure changes. It is not an annual report, earnings release, or other report type, but specifically a prospectus supplement related to a share offering.
2026-04-16 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.